The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Perspective
PreviousPrevious
Volume 357:2219-2221 November 29, 2007 Number 22
NextNext

In Defense of Pharmacoepidemiology — Embracing the Yin and Yang of Drug Research
Jerry Avorn, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
The past decade has not been kind to observational studies of medications. The damage began in 1998 with the publication of the Heart and Estrogen–Progestin Replacement Study, a randomized controlled trial showing that hormone replacement increased the risk of cardiac events among postmenopausal women with heart disease. Like many physicians, I had been teaching the gospel that estrogen use prevented heart disease — an idea based on observational studies1 showing that postmenopausal women who regularly took estrogen were less likely to have heart disease than apparently similar women who did not take hormones. It now appeared that this had been . . . [Full Text of this Article]


Source Information

Dr. Avorn is a professor of medicine at Harvard Medical School and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital — both in Boston.



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.